Shaw Appointed Advisor to Visby Medical: Advances in Molecular Diagnostics including Rapid COVID-19 PCR Test
July 2021, by David E. Shaw
I am grateful to serve as an advisor to Visby Medical, supporting development and commercialization of the company’s advanced instrument-free molecular diagnostic PCR technology, including FDA Emergency Use Authorization for their Visby Medical COVID-19 test, and their COVID-19 Point of Care test.
Amidst the COVID-19 pandemic, Visby Medical technology is playing a leading role in providing the fast, accurate results needed to protect vulnerable populations, such as frontline health workers and long-term care residents, as well as employees and travelers. While rapid antigen tests exist, the Visby PCR device is the first instrument-free – therefore deployable — test that provides gold-standard accurate results in under 30 minutes. This sets the Visby Medical technology apart as an alternative to longer lead-times associated with central laboratory testing.
Congratulations to founder and CEO Adam de la Zerda, PhD, and the Visby Medical team, for their remarkable accomplishments in developing technology to meet diagnostic needs for COVID-19 and many other applications in the future. More information about the company can be found HERE.